Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Scot Ebbinghaus"'
Autor:
Tian Zhang, Patrick M Forde, Elad Sharon, Scot Ebbinghaus, Michael B Atkins, Mark Stewart, Ryan J Sullivan, Elizabeth Barksdale, Wendy Selig, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment setting
Externí odkaz:
https://doaj.org/article/48319baa5c5a4d68b9c0d564b37e5e92
Autor:
Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun (Nicole) Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim, Scot Ebbinghaus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract Background In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether
Externí odkaz:
https://doaj.org/article/60dea824a8844112b8bcde99be6f54a2
Autor:
Tara C. Gangadhar, Keaven M. Anderson, Scot Ebbinghaus, S. Peter Kang, Jin Zhang, Andrea Perrone, Dinesh P. de Alwis, Amita Patnaik, Jeffrey S. Weber, Peter Hersey, Roxana Dronca, Adil Daud, Caroline Robert, Omid Hamid, F. Stephen Hodi, Antoni Ribas, Anthony M. Joshua, Jedd D. Wolchok, Wen-Jen Hwu, Richard Kefford, Jeroen Elassaiss-Schaap, Richard W. Joseph
Supplemental Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26176e6e3787608edb4bcad0a45a1799
https://doi.org/10.1158/1078-0432.22468532.v1
https://doi.org/10.1158/1078-0432.22468532.v1
Autor:
Tara C. Gangadhar, Keaven M. Anderson, Scot Ebbinghaus, S. Peter Kang, Jin Zhang, Andrea Perrone, Dinesh P. de Alwis, Amita Patnaik, Jeffrey S. Weber, Peter Hersey, Roxana Dronca, Adil Daud, Caroline Robert, Omid Hamid, F. Stephen Hodi, Antoni Ribas, Anthony M. Joshua, Jedd D. Wolchok, Wen-Jen Hwu, Richard Kefford, Jeroen Elassaiss-Schaap, Richard W. Joseph
Supplemental Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a18324eda47ea878342d3c1bbc476eab
https://doi.org/10.1158/1078-0432.22468538
https://doi.org/10.1158/1078-0432.22468538
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Table 1. Hits from the dalotuzumab enhancer screen. Supplementary Table 2. Patient and disease characteristics. Supplementary Table 3. Summary of dose-limiting toxicities. Supplementary Table 4. Summary of clinical efficacy in breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025a26d870c9fda45bccdde6460658d4
https://doi.org/10.1158/1078-0432.22454814.v1
https://doi.org/10.1158/1078-0432.22454814.v1
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 1. Treatment and pharmacodynamic assessment schedules.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f2f3ed94a6bd56e383704d713371c7
https://doi.org/10.1158/1078-0432.22454826
https://doi.org/10.1158/1078-0432.22454826
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32284213cd5fddddd74502300a970e96
https://doi.org/10.1158/1078-0432.c.6522843.v1
https://doi.org/10.1158/1078-0432.c.6522843.v1
Autor:
Tara C. Gangadhar, Keaven M. Anderson, Scot Ebbinghaus, S. Peter Kang, Jin Zhang, Andrea Perrone, Dinesh P. de Alwis, Amita Patnaik, Jeffrey S. Weber, Peter Hersey, Roxana Dronca, Adil Daud, Caroline Robert, Omid Hamid, F. Stephen Hodi, Antoni Ribas, Anthony M. Joshua, Jedd D. Wolchok, Wen-Jen Hwu, Richard Kefford, Jeroen Elassaiss-Schaap, Richard W. Joseph
Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::558661f46534a160d0f58b8432cced12
https://doi.org/10.1158/1078-0432.c.6526982.v1
https://doi.org/10.1158/1078-0432.c.6526982.v1
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 3. Change in Ki67 levels with ridaforolimus and dalotuzumab combination therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad0fb5dc49be6c69df85bf35b08f9e5
https://doi.org/10.1158/1078-0432.22454820.v1
https://doi.org/10.1158/1078-0432.22454820.v1
Autor:
Tara C. Gangadhar, Keaven M. Anderson, Scot Ebbinghaus, S. Peter Kang, Jin Zhang, Andrea Perrone, Dinesh P. de Alwis, Amita Patnaik, Jeffrey S. Weber, Peter Hersey, Roxana Dronca, Adil Daud, Caroline Robert, Omid Hamid, F. Stephen Hodi, Antoni Ribas, Anthony M. Joshua, Jedd D. Wolchok, Wen-Jen Hwu, Richard Kefford, Jeroen Elassaiss-Schaap, Richard W. Joseph
Figure legends for supplemental figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c73bef84a8d535a428e2124f7d23a8e
https://doi.org/10.1158/1078-0432.22468544
https://doi.org/10.1158/1078-0432.22468544